Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma
NCT ID: NCT02961816
Last Updated: 2017-04-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE2
INTERVENTIONAL
2017-06-30
2021-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
High-Dose Gemcitabine, Busulfan and Melphalan for Patients With Refactory Hodgkin's Disease
NCT01200329
Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant
NCT03259503
CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma
NCT01746173
A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma
NCT02532192
Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
NCT01261247
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Participant will receive a test dose of busulfan by vein over about 60 minutes. Before and after participant receives this low-level test dose of busulfan, blood will be drawn several times to check how the level of busulfan in participant's blood changes over time. This is called pharmacokinetic (PK) testing. This information will be used to decide the next dose needed to reach the correct blood level that matches participant's body size. Participant will most likely receive this test dose as an outpatient during the week before participant is admitted to the hospital. If it cannot be given as an outpatient, participant will be admitted to the hospital on Day -11 (11 days before participant's stem cells are returned to participant's body) and the test dose will be given on Day -10.
Blood (about 1 teaspoon each time) will be drawn for PK testing about 11 times before participant's test dose of busulfan and 10 times over the 11 hours after the dose. The blood samples will be repeated again on the first day of high-dose busulfan treatment (Day -8). A temporary heparin lock line will be placed in participant's vein to lower the number of needle sticks needed for these draws.
If it is not possible for the PK tests to be performed for any reason, participant will receive the standard fixed dose of busulfan.
Study Drug Administration:
On Days -13 through -11 (the 3 days before participant is admitted to the hospital), participant will receive palifermin by vein over about 30 seconds each day to help decrease the risk of side effects in the mouth and throat.
On Day -9 through Day -2, participant will take panobinostat by mouth, with food. The study staff will tell participant how many tablets to take. Participant will receive dexamethasone by vein over about 3-5 minutes 2 times each day.
On Day -9, if participant has a type of B-cell cancer, participant will receive rituximab (a treatment used for certain lymphomas) by vein over about 3-6 hours as part of participant's standard care. The study doctor will tell participant if participant will receive rituximab.
On Day -8, participant will receive gemcitabine by vein over 4½ hours.
On Days -8, -7, -6, and -5, participant will receive busulfan by vein over about 60 minutes.
On Day -3, participant will receive gemcitabine by vein over 4½ hours and then melphalan by vein over 30 minutes.
On Day -2, participant will receive melphalan by vein over 30 minutes.
On Day -1, participant will rest (participant will not receive chemotherapy).
On Day 0, participant will receive participant's stem cells by vein over about 30-60 minutes.
Participant will receive 3 more doses of palifermin by vein, over 15-30 seconds each time, on Days 0, +1, and +2.
As part of standard care, participant will receive G-CSF (filgrastim) as an injection just under participant's skin 1 time each day starting on Day +5 until participant's blood cell levels return to normal. The study doctor will discuss this with participant, including how filgrastim is given and its risks.
Length of Study:
As part of standard care, participant will remain in the hospital for about 3-4 weeks after the transplant. After participant is released from the hospital, participant will continue as an outpatient. Participant will need to stay in the Houston area to be checked for infections and side effects.
Participant will be taken off study about 100 days after the transplant. Participant may be taken off study earlier if the disease gets worse, if intolerable side effects occur, or if participant is unable to follow study directions.
Study Tests:
About 100 days after the transplant:
* Participant will have a physical exam.
* Blood (about 4 teaspoons) and urine will be collected for routine tests.
* If the doctor thinks it is needed, participant may have a bone marrow aspiration and biopsy to check the status of the disease. To collect a bone marrow aspiration/biopsy, an area of the hip is numbed with anesthetic, and a small amount of bone marrow and bone is withdrawn through a large needle.
This is an investigational study. Panobinostat and melphalan are FDA approved and commercially available for the treatment of multiple myeloma (MM). Busulfan is FDA approved and commercially available for the treatment of leukemia. Gemcitabine is FDA approved and commercially available for the treatment of lymphoma, breast cancer, and lung cancer. Rituximab is FDA approved and commercially available for the treatment of non-Hodgkin's lymphoma.
The use of these study drugs in combination is investigational. The study doctor can explain how the study drugs are designed to work.
Up to 75 participants will take part in this study. All will be enrolled at MD Anderson.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort A: Diffuse Large B-Cell Lymphoma
Palifermin on Days -13 to -11 and on Days 0, +1, and +2.
Panobinostat daily from Day -9 to -2.
Gemcitabine administered on Days -8 and -3.
Busulfan test dose administered on day -10. Doses of Days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1. Busulfan adjusted to target a cumulative AUC of 16000 and may be significantly higher or lower than 4000 on the last 2 days depending on first PK.
Melphalan on Days -3 and -2.
Rituximab on Day -9 for participants with CD20+ tumors.
Dexamethasone twice a day from Day -8 AM to Day -2 PM.
Caphosol oral rinses 30 mL four times a day used from Day -8.
Oral glutamine, 15 g four times a day, swished, gargled and swallowed started on Day -8.
Pyridoxine three times a day from Day -1.
Stem cells administered by vein on Day 0.
G-CSF 1 time each day starting on Day +5 until blood cell levels return to normal.
Palifermin
Palifermin, per standard of care, on Days -13 to -11 and on Days 0, +1, and +2.
Panobinostat
20 mg by mouth daily from Day -9 to -2.
Gemcitabine
Gemcitabine administered as a loading dose of 75 mg/m2 by vein followed by prolonged infusion over 4.5 hours of 2,700 mg/m2 (total daily dose 2,775 mg/m2) on Days -8 and -3.
Busulfan
Busulfan "test dose" administered on Day -10. Test dose of 32 mg/m2 based on actual body weight administrated over 60 minutes. Busulfan pharmacokinetics performed with the test dose and the first dose on Day-8. Doses of Days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1. Busulfan adjusted to target a cumulative AUC of 16000 and may be significantly higher or lower than 4000 on the last 2 days depending on first PK.
Melphalan
60 mg/m2 by vein on Days -3 and -2.
Rituximab
375 mg/m2 by vein on Day -9 for patients with CD20+ tumors.
Dexamethasone
8 mg by vein twice a day from Day -8 AM to Day -2 PM.
Caphosol
Caphosol oral rinses 30 mL four times a day used from Day -8.
Glutamine
Oral Glutamine, 15 g four times a day, swished, gargled and swallowed started on Day -8.
Oral Cryotherapy (ice chips)
Oral cryotherapy (ice chips) from 30 minutes before until 2 hours after each Melphalan infusion.
Pyridoxine
100 mg by vein or mouth three times a day from Day -1.
Stem Cell Infusion
Stem cells administered by vein on Day 0.
G-CSF
G-CSF administered as an injection just under the skin, per standard of care ,1 time each day starting on Day +5 until blood cell levels return to normal.
Cohort B: Hodgkin's Lymphoma
Palifermin on Days -13 to -11 and on Days 0, +1, and +2.
Panobinostat daily from Day -9 to -2.
Gemcitabine administered on Days -8 and -3.
Busulfan test dose administered on day -10. Doses of Days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1. Busulfan adjusted to target a cumulative AUC of 16000 and may be significantly higher or lower than 4000 on the last 2 days depending on first PK.
Melphalan on Days -3 and -2.
Rituximab on Day -9 for participants with CD20+ tumors.
Dexamethasone twice a day from Day -8 AM to Day -2 PM.
Caphosol oral rinses 30 mL four times a day used from Day -8.
Oral glutamine, 15 g four times a day, swished, gargled and swallowed started on Day -8.
Pyridoxine three times a day from Day -1.
Stem cells administered by vein on Day 0.
G-CSF 1 time each day starting on Day +5 until blood cell levels return to normal.
Palifermin
Palifermin, per standard of care, on Days -13 to -11 and on Days 0, +1, and +2.
Panobinostat
20 mg by mouth daily from Day -9 to -2.
Gemcitabine
Gemcitabine administered as a loading dose of 75 mg/m2 by vein followed by prolonged infusion over 4.5 hours of 2,700 mg/m2 (total daily dose 2,775 mg/m2) on Days -8 and -3.
Busulfan
Busulfan "test dose" administered on Day -10. Test dose of 32 mg/m2 based on actual body weight administrated over 60 minutes. Busulfan pharmacokinetics performed with the test dose and the first dose on Day-8. Doses of Days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1. Busulfan adjusted to target a cumulative AUC of 16000 and may be significantly higher or lower than 4000 on the last 2 days depending on first PK.
Melphalan
60 mg/m2 by vein on Days -3 and -2.
Rituximab
375 mg/m2 by vein on Day -9 for patients with CD20+ tumors.
Dexamethasone
8 mg by vein twice a day from Day -8 AM to Day -2 PM.
Caphosol
Caphosol oral rinses 30 mL four times a day used from Day -8.
Glutamine
Oral Glutamine, 15 g four times a day, swished, gargled and swallowed started on Day -8.
Oral Cryotherapy (ice chips)
Oral cryotherapy (ice chips) from 30 minutes before until 2 hours after each Melphalan infusion.
Pyridoxine
100 mg by vein or mouth three times a day from Day -1.
Stem Cell Infusion
Stem cells administered by vein on Day 0.
G-CSF
G-CSF administered as an injection just under the skin, per standard of care ,1 time each day starting on Day +5 until blood cell levels return to normal.
Cohort C: T-Cell Lymphoma
Palifermin on Days -13 to -11 and on Days 0, +1, and +2.
Panobinostat daily from Day -9 to -2.
Gemcitabine administered on Days -8 and -3.
Busulfan test dose administered on day -10. Doses of Days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1. Busulfan adjusted to target a cumulative AUC of 16000 and may be significantly higher or lower than 4000 on the last 2 days depending on first PK.
Melphalan on Days -3 and -2.
Rituximab on Day -9 for participants with CD20+ tumors.
Dexamethasone twice a day from Day -8 AM to Day -2 PM.
Caphosol oral rinses 30 mL four times a day used from Day -8.
Oral glutamine, 15 g four times a day, swished, gargled and swallowed started on Day -8.
Pyridoxine three times a day from Day -1.
Stem cells administered by vein on Day 0.
G-CSF 1 time each day starting on Day +5 until blood cell levels return to normal.
Palifermin
Palifermin, per standard of care, on Days -13 to -11 and on Days 0, +1, and +2.
Panobinostat
20 mg by mouth daily from Day -9 to -2.
Gemcitabine
Gemcitabine administered as a loading dose of 75 mg/m2 by vein followed by prolonged infusion over 4.5 hours of 2,700 mg/m2 (total daily dose 2,775 mg/m2) on Days -8 and -3.
Busulfan
Busulfan "test dose" administered on Day -10. Test dose of 32 mg/m2 based on actual body weight administrated over 60 minutes. Busulfan pharmacokinetics performed with the test dose and the first dose on Day-8. Doses of Days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1. Busulfan adjusted to target a cumulative AUC of 16000 and may be significantly higher or lower than 4000 on the last 2 days depending on first PK.
Melphalan
60 mg/m2 by vein on Days -3 and -2.
Rituximab
375 mg/m2 by vein on Day -9 for patients with CD20+ tumors.
Dexamethasone
8 mg by vein twice a day from Day -8 AM to Day -2 PM.
Caphosol
Caphosol oral rinses 30 mL four times a day used from Day -8.
Glutamine
Oral Glutamine, 15 g four times a day, swished, gargled and swallowed started on Day -8.
Oral Cryotherapy (ice chips)
Oral cryotherapy (ice chips) from 30 minutes before until 2 hours after each Melphalan infusion.
Pyridoxine
100 mg by vein or mouth three times a day from Day -1.
Stem Cell Infusion
Stem cells administered by vein on Day 0.
G-CSF
G-CSF administered as an injection just under the skin, per standard of care ,1 time each day starting on Day +5 until blood cell levels return to normal.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Palifermin
Palifermin, per standard of care, on Days -13 to -11 and on Days 0, +1, and +2.
Panobinostat
20 mg by mouth daily from Day -9 to -2.
Gemcitabine
Gemcitabine administered as a loading dose of 75 mg/m2 by vein followed by prolonged infusion over 4.5 hours of 2,700 mg/m2 (total daily dose 2,775 mg/m2) on Days -8 and -3.
Busulfan
Busulfan "test dose" administered on Day -10. Test dose of 32 mg/m2 based on actual body weight administrated over 60 minutes. Busulfan pharmacokinetics performed with the test dose and the first dose on Day-8. Doses of Days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1. Busulfan adjusted to target a cumulative AUC of 16000 and may be significantly higher or lower than 4000 on the last 2 days depending on first PK.
Melphalan
60 mg/m2 by vein on Days -3 and -2.
Rituximab
375 mg/m2 by vein on Day -9 for patients with CD20+ tumors.
Dexamethasone
8 mg by vein twice a day from Day -8 AM to Day -2 PM.
Caphosol
Caphosol oral rinses 30 mL four times a day used from Day -8.
Glutamine
Oral Glutamine, 15 g four times a day, swished, gargled and swallowed started on Day -8.
Oral Cryotherapy (ice chips)
Oral cryotherapy (ice chips) from 30 minutes before until 2 hours after each Melphalan infusion.
Pyridoxine
100 mg by vein or mouth three times a day from Day -1.
Stem Cell Infusion
Stem cells administered by vein on Day 0.
G-CSF
G-CSF administered as an injection just under the skin, per standard of care ,1 time each day starting on Day +5 until blood cell levels return to normal.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients with: DLBCL with one of the following: 1. Primary refractory (no CR to 1st line); 2. High-risk relapse (CR1 \<6 months, secondary IPI \>1 or high LDH); or, 3. Refractory relapse: No response (SD or PD) to \>/= 1 line of salvage.
3. Hodgkin's with one of the following: 1. Primary refractory (no CR to 1st line or PD within 3 months); 2. High-risk relapse (CR1 \<1 year, extranodal relapse or B symptoms); or, 3. Refractory relapse: No response (SD or PD) to \>/= 1 line of salvage.
4. T-NHL with one of the following: 1. Primary refractory (\</= CR to 1st line or relapse within 6 months); or, 2. Nonresponsive (SD/PD) to \>/= 1 line of salvage.
5. Adequate renal function, as defined by estimated serum creatinine clearance \>/= 50 ml/min and/or serum creatinine \</= 1.8 mg/dL
6. Adequate hepatic function (SGOT and/or serum glutamate pyruvate transaminase (SGPT) \</= 3 x upper limit of normal (ULN); bilirubin and ALP \</= 2 x ULN
7. Adequate pulmonary function with forced expiratory volume at one second (FEV1), forced vital capacity (FVC) and diffusing capacity of lung for carbon monoxide (DLCO) (corrected for Hgb) \>/= 50%
8. Adequate cardiac function with left ventricular ejection fraction \>/= 40%. No uncontrolled arrhythmias or symptomatic cardiac disease
9. PS \<2
10. Negative Beta human chorionic gonadotropin (HCG) in woman with child-bearing potential
Exclusion Criteria
2. Prior whole brain irradiation
3. Corrected QT interval (QTc) longer than 500 ms
4. Active hepatitis B, either active carrier (HBsAg +) or viremic (HBV DNA \>/= 10,000 copies/mL, or \>/= 2,000 IU/mL)
5. Evidence of either cirrhosis or stage 3-4 liver fibrosis in patients with chronic hepatitis C or positive hepatitis C serology
6. Active infection requiring parenteral antibiotics
7. HIV infection, unless receiving effective antiretroviral therapy with undetectable viral load and normal cluster of differentiation 4 (CD4) counts
8. Radiation therapy in the month prior to enroll
15 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
M.D. Anderson Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yago Nieto, MD, PHD
Role: PRINCIPAL_INVESTIGATOR
M.D. Anderson Cancer Center
Related Links
Access external resources that provide additional context or updates about the study.
University of Texas MD Anderson Cancer Center Website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2016-01914
Identifier Type: REGISTRY
Identifier Source: secondary_id
2016-0074
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.